"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
| Descriptor ID |
D000276
|
| MeSH Number(s) |
D27.505.696.477.067
|
| Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 2 | 3 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 3 | 5 |
| 2014 | 1 | 7 | 8 |
| 2015 | 1 | 5 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 38 | 40 | 78 |
| 2018 | 30 | 37 | 67 |
| 2019 | 18 | 19 | 37 |
| 2020 | 11 | 14 | 25 |
| 2021 | 9 | 13 | 22 |
To return to the timeline, click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens. Recent Pat Biotechnol. 2021 Oct 04; 15(2):112-136.
-
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci U S A. 2021 09 21; 118(38).
-
Inhibition of elastase enhances the adjuvanticity of alum and promotes anti-SARS-CoV-2 systemic and mucosal immunity. Proc Natl Acad Sci U S A. 2021 08 24; 118(34).
-
Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19. Int J Pharm. 2021 Sep 25; 607:121024.
-
Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection. mBio. 2021 08 31; 12(4):e0159821.
-
Large-Sized Graphene Oxide Nanosheets Increase DC-T-Cell Synaptic Contact and the Efficacy of DC Vaccines against SARS-CoV-2. Adv Mater. 2021 Oct; 33(40):e2102528.
-
Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production. Sci Adv. 2021 08; 7(32).
-
Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist. J Med Chem. 2021 08 12; 64(15):11554-11569.
-
Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. Mol Pharm. 2021 08 02; 18(8):2867-2888.
-
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).